🇺🇸 FDA
Patent

US 8828971

Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders

granted A61KA61K31/7105A61K31/715

Quick answer

US patent 8828971 (Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders) held by GALECTIN THERAPEUTICS, INC. expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
GALECTIN THERAPEUTICS, INC.
Grant date
Tue Sep 09 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/7105, A61K31/715, A61K38/02, A61K45/06